TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/06/2023
Voltar para busca
Dado oficial do USPTO
9METERS BIOPHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
9METERS BIOPHARMA
ST13
US500000088983913Classe
42
Pedido
88983913
Registro
6725571
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
08/07/2023
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
09/08/2019
Data de registro
24/05/2022
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/05/2022
Última transação
08/07/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2020-07-00
Primeiro uso no comércio
2020-07-00
Código do desenho
4
Tipo de titular
03
Localização do titular
Raleigh, NC
Examinador
EISNACH, MICHAEL
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
9 METERS BIOPHARMA
9 METERS BIOPHARMA
RDD Pharma, Inc.
Representantes
Devon E. White WYRICK ROBBINS YATES & PONTON LLP
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Pharmaceutical research and development services; Medical and scientific research information in the field of novel pharmaceutical discovery and development; Research and development in the pharmaceutical and biotechnology fields; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Medical and scientific researchconducting clinical trials for others of New Therapeutic Entities (NTEs) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither New Chemical Entities (NCEs) nor generics and New Chemical Entities (NCEs) and Biologic License Application (BLAs) as novel pharmaceutical treatments; Research and development in the field of New Therapeutic Entities (NTEs) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither New Chemical Entities (NCEs) nor generics and New Chemical Entities (NCEs) and Biologic License Application (BLAs) as novel pharmaceutical treatments; Research and development in the field of novel pharmaceutical treatments and clinical trials; Providing medical and scientific research information in the field of novel pharmaceutical treatments and clinical trials; Clinical trials services for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/06/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/06/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
30/06/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
30/06/2023
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
26/04/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
24/05/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
24/05/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/04/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/04/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/03/2022
DPCC
DIVISIONAL PROCESSING COMPLETE
04/03/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
28/02/2022
IUAF
USE AMENDMENT FILED
11/02/2022
DRRR
DIVISIONAL REQUEST RECEIVED
11/02/2022
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
11/02/2022
EISU
TEAS STATEMENT OF USE RECEIVED
11/02/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
22/12/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
20/08/2021
EX3G
SOU EXTENSION 3 GRANTED
18/08/2021
EXT3
SOU EXTENSION 3 FILED
18/08/2021
EEXT
SOU TEAS EXTENSION RECEIVED
18/08/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/12/2020
EX2G
SOU EXTENSION 2 GRANTED
10/12/2020
EXT2
SOU EXTENSION 2 FILED
10/12/2020
EEXT
SOU TEAS EXTENSION RECEIVED
10/12/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
15/08/2020
EX1G
SOU EXTENSION 1 GRANTED
13/08/2020
EXT1
SOU EXTENSION 1 FILED
13/08/2020
EEXT
SOU TEAS EXTENSION RECEIVED
13/08/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
18/02/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/12/2019
PUBO
PUBLISHED FOR OPPOSITION
24/12/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/12/2019
ALIE
ASSIGNED TO LIE
18/11/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/11/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
14/11/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/11/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
14/11/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/11/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/11/2019
GNRT
NON-FINAL ACTION E-MAILED
14/11/2019
CNRT
NON-FINAL ACTION WRITTEN
14/11/2019
DOCK
ASSIGNED TO EXAMINER
07/11/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/08/2019
NWAP
NEW APPLICATION ENTERED
13/08/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace 9METERS BIOPHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.